Experimental evidence supports an antineoplastic activity of marine ω-3 polyunsaturated fatty acids.
However, the influence of ω-3 PUFAs on colorectal cancer survival is unknown.
Within the Nurses' Health Study and Health Professionals Follow-up Study, Dr Mingyang Song and colleagues from Massachusetts, USA prospectively studied colorectal cancer-specific and overall mortality in a cohort of 1659 patients with colorectal cancer according to intake of marine ω-3 PUFAs and its change after diagnosis.
Higher intake of marine ω-3 PUFAs after colorectal cancer diagnosis was associated with lower risk of colorectal cancer-specific mortality.
|An increased ω-3 PUFA intake by 0.15 g/day after diagnosis had a hazard ratio of 0.30 for colorectal cancer deaths|
The team found that compared with patients who consumed less than 0.10 g/day of marine ω-3 PUFAs, those consuming at least 0.30 g/day had an adjusted hazard ratio for colorectal cancer-specific mortality of 0.59.
The researchers observed that patients who increased their marine ω-3 PUFA intake by at least 0.15 g/day after diagnosis had a hazard ratio of 0.30 for colorectal cancer deaths, compared with those who did not change or changed their intake by less than 0.02 g/day.
The team noted no association between postdiagnostic marine ω-3 PUFA intake and all-cause mortality.
Dr Song's team comments, "High marine ω-3 PUFA intake after colorectal cancer diagnosis is associated with lower risk of colorectal cancer-specific mortality."
"Increasing consumption of marine ω-3 PUFAs after diagnosis may confer additional benefits to patients with colorectal cancer."